Literature DB >> 15372606

Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms.

Katerina Venderová1, Evzen Růzicka, Viktor Vorísek, Peter Visnovský.   

Abstract

An anonymous questionnaire sent to all patients attending the Prague Movement Disorder Centre revealed that 25% of 339 respondents had taken cannabis and 45.9% of these described some form of benefit.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15372606     DOI： 10.1002/mds.20111

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  38 in total

Review 1.  Evidence for the use of cannabinoids in Parkinson's disease.

Authors:  Carsten Buhmann; Tina Mainka; Georg Ebersbach; Florin Gandor
Journal:  J Neural Transm (Vienna)       Date:  2019-05-27       Impact factor: 3.575

Review 2.  Cannabis in the Treatment of Dystonia, Dyskinesias, and Tics.

Authors:  Barbara S Koppel
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 3.  Mechanisms for alternative treatments in Parkinson's disease: acupuncture, tai chi, and other treatments.

Authors:  Bijan D Ghaffari; Benzi Kluger
Journal:  Curr Neurol Neurosci Rep       Date:  2014-06       Impact factor: 5.081

4.  Neuroanatomical correlates of the inhibition of tremulous jaw movements in rats by a combination of memantine and Δ9 -tetrahydrocannabinol.

Authors:  Ilya D Ionov; Irina I Pushinskaya; David D Frenkel; Niсholas P Gorev; Larissa A Shpilevaya
Journal:  Br J Pharmacol       Date:  2020-01-24       Impact factor: 8.739

Review 5.  Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.

Authors:  Eva Schaeffer; Andrea Pilotto; Daniela Berg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 6.  Molecular imaging of levodopa-induced dyskinesias.

Authors:  Flavia Niccolini; Lorenzo Rocchi; Marios Politis
Journal:  Cell Mol Life Sci       Date:  2015-02-15       Impact factor: 9.261

7.  Inhibition of striatal dopamine release by CB1 receptor activation requires nonsynaptic communication involving GABA, H2O2, and KATP channels.

Authors:  Zsuzsanna Sidló; Patricia H Reggio; Margaret E Rice
Journal:  Neurochem Int       Date:  2007-07-22       Impact factor: 3.921

Review 8.  Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Authors:  José Alexandre S Crippa; Jaime E C Hallak; Antônio W Zuardi; Francisco S Guimarães; Vitor Tumas; Rafael G Dos Santos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-31       Impact factor: 5.270

Review 9.  The therapeutic potential of cannabinoids for movement disorders.

Authors:  Benzi Kluger; Piera Triolo; Wallace Jones; Joseph Jankovic
Journal:  Mov Disord       Date:  2015-02-04       Impact factor: 10.338

Review 10.  Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe?

Authors:  Shokouh Arjmand; Zohreh Vaziri; Mina Behzadi; Hassan Abbassian; Gary J Stephens; Mohammad Shabani
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.